Global Akeega sales will reach $676 million by 2030, while Talzenna and saruparib reach $618 million and $628 million ...

Akeega – which combines the active ingredients in J&J's PARP inhibitor Zejula (niraparib) and androgen blocker Zytiga ...

The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...

The former Pfizer headquarters property, located at 219 and 235 East 42nd Street in Manhattan’s Midtown East area, is set to be transformed into a residential complex with 1,602 units. Construction is ...

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) stock is trading back down near its pandemic lows. Every time it attempts to climb over the $30 mark, something causes shares to slide right back down.

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously (8 to 0) against the risk-benefit profile of talazoparib (Talzenna) combined with enzalutamide (Xtandi) for the treatment of ...

Pfizer's commitment to returning capital to ... lymphoma and encouraging clinical data for Padcev in urothelial cancer. Talzenna also showed positive overall survival data in prostate cancer ...

CompanyOverview\|NYSE:PFE] A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income- ...

FDA advisors unanimously voted against expanding Pfizer’s Talzenna to a broader prostate cancer population without HRR mutations, citing flaws in trial design, insufficient statistical power, and ...

Pfizer’s phase 3 Talapro-2 trial, which compared a Talzenna-Xtandi cocktail with Xtandi alone, recently met both progression-free survival and overall survival endpoints in a first-line mCRPC ...

The FDA’s independent advisors found Pfizer’s data lacked the precision needed to establish the efficacy of Talzenna in patients with prostate cancer who do not carry HRR mutations. The FDA’s ...